Tumors Evade T-Cell Recognition by Hiding p53 Neoantigens, Dana-Farber Research Reveals
New research led by the Dana-Farber Cancer Institute and Harvard Medical School has uncovered a mechanism by which tumors can evade detection by the immune system, specifically T-cells. The study, published in Immunity, found that despite the prevalence of TP53 mutations in cancer, which are attractive targets for personalized immunotherapies, tumors can actively restrict the presentation of p53-derived neoantigens on their surface. This means that even if a tumor has a mutation predicted to produce a strong neoantigen, the resulting peptide may not be processed, loaded onto a human leukocyte antigen (HLA) molecule, or displayed at sufficient levels on the tumor surface for T-cells to recognize it. The researchers utilized an ultrasensitive mass spectrometry-based immunopeptidomics platform, combined with tumor genomics, structural biology, and engineered T-cells, to directly investigate p53 peptide presentation.